Company Overview and News

341
BIIB Stock Price - Biogen Inc. Stock Quote (U.S.: Nasdaq) - MarketWatch

2018-06-18 marketwatch
AstraZeneca PLC and Eli Lilly & Co. on Tuesday scrapped two late-stage trials of an experimental Alzheimer's drug they were co-developing, the latest blow in the long quest to find a breakthrough for the memory-robbing disorder.
REGN IRWD CELGZ AZN TEVA MS.PRE TEVVF MS.PRF MS.PRG MS.PRA MS.PRI TEVJF BIIB ALXN MS.PRK IONS CELG MS

2087
20 Nasdaq-100 Stocks That Will Heat Up 2H18

2018-06-15 investorplace
Unless you’ve been living under a rock, you know that the narrative surrounding broad markets — it’s been one of strife since late January until the recent rally. Volatility spiked and the S&P 500 Index still sits almost 3% below late-January highs.
LRCX TEVA GS.PRB GS.PRA CDNS DLTR GLSSP FEYE AMZN ALXN AMAT CELG AVGO EBAY SNAP JBK QQQ TTWO TFG VRX CHKP CA CTSH MAR GS.PRJ GS.PRI BABA EXPE ORBK GOOGL GS.PRD GS.PRC QCOM GS.PRN GS.PRK JD XLNX FB ULTA ADP MNST TEVVF PYPL NFLX AMD NVDA GOOG KLAC ATVI MAR.WI GS MYL AAPL KO PAYX IBM EA CELGZ GSC GS.PRICL PANW GSJ BKNG ADPVV TEVJF MU DG MNK BRCM GJS

481
Your Daily Pharma Scoop: Tetraphase Positive Data, MediWound In Phase 3, Allergan Moves Up

2018-06-13 seekingalpha
Tetraphase Pharma (TTPH) has a PDUFA on August 28 for its lead drug candidate ERAVACYCLINE in one indication - cIAI - complicated intra-abdominal infections. This PDUFA is based on an NDA filed on Feb 27 - the 6-month duration comes from a Fast Track designation; they also have a Qualified Infectious Disease Product (‘QIDP) for the drug candidate.
NTLA MKGAF OPK RCUS CORV ENL AQXP CUR EDIT ALXN AGN ADXS PFNX GTBP AMGN VTGN CRSP MDWD LLY SNY VICL LIVN MKGAY LIVN ENDP

370
Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod

2018-06-13 zacks
The biotech sector was in focus last week with regular pipeline updates and collaboration/licensing deals. While biotech bigwig Amgen’s (AMGN - Free Report) drugs won both FDA and EC approvals, Axovant (AXON - Free Report) soared on a licensing deal Oxford BioMedica. Meanwhile, Regeneron (REGN - Free Report) collaborated with Zoetis to discover new veterinary treatments.
AMGN ALXN BIIB OXB OXBDF AXON

41
ALXN / Alexion Pharmaceuticals, Inc. 8-K (Current Report)

2018-06-13 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
ALXN

211
10 Stocks That Are Screaming Buys Right Now

2018-06-12 investorplace
Buckle up — the market is looking jittery right now. If it’s not the threat of further Federal interest rate hikes, it’s the possibility of a full-blown trade war with China and Europe. As James Brumley notes, however, if geopolitical risks were actually a deterrent to investing “nobody would ever put (or keep) a penny in stocks”.
MTZ FB VRTX BABA TWOU ALXN BOE PXD RTN SKX BA

287
Short Sellers Up the Ante For Major Biotechs

2018-06-12 247wallst
The short interest data are out for the most recent settlement date, May 31. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks with big potential upside and big potential downside.
MNKD AMGN CELGZ BIIB GILD ALXN CELG

132
Alexion-Complement Pharma Tie Up to Treat Neuro Disorders

2018-06-12 zacks
Alexion Pharmaceuticals, Inc. (ALXN - Free Report) announced a partnership with Complement Pharma to co-develop the preclinical C6 complement inhibitor, CP010, for neurodegenerative disorders.
ALXN JUNO CELG SNY BIVV

40
Alexion Pharma Dives Into C6 Inhibition in a Development Deal That Could Lead to Acquisition of C...

2018-06-11 biospace
With plans to seek regulatory approval for ALXN1210, long-acting C5 complement inhibitor seen as a successor to the blockbuster drug Soliris, Alexion Pharmaceuticals is forging a partnership with Complement Pharma to co-develop a C6 complement inhibitor.
ALXN

40
ALXN / Alexion Pharmaceuticals, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - null (Passive Investment)

2018-06-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 20) ALEXION PHARMACEUTICALS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 015351109 (CUSIP NUMBER) May 31, 2018 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1.
ALXN

40
ALXN / Alexion Pharmaceuticals, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - null (Passive Investment)

2018-06-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 20) ALEXION PHARMACEUTICALS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 015351109 (CUSIP NUMBER) May 31, 2018 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1.
ALXN

80
Biogen’s O’Neill Heads to Sarepta Therapeutics

2018-06-08 biospace
Gilmore O’Neill, formerly Biogen’s senior vice president, late-stage clinical development, jumped ship and will be Sarepta Therapeutics’ chief medical officer.
REGN ALXN NG IONS NGGTF SRPT NGG

633
Core Biotech Buys #18: Thoughts On ASCO And The End Of Core Biotech

2018-06-07 seekingalpha
Novocure strengthened its Board of Directors and Abeona Therapeutics received a key analyst thumbs up. Two possible trades are suggested.
SGEN NKTR DCPH ATRS NVCR PTLA LOXO CORT ONCE BPMC HNCMF DVAX BIIB ALXN GSK BLUE BMY MOR EXEL BLUE XNCR INCY NBIX GLPG ABEO AKCA HCM HCM ADMS GSK JNCE MRK IONS NVS ABEOW ARRY

149
Institutional Top Ideas Series: Biotechnology Value Fund

2018-06-04 seekingalpha
BVF returns have really ramped up recently, made more impressive by their lower turnover compared to other funds we´ve looked at.
SGEN SNSS CCXI ALXN IDRAW IDRA XNCR XENE

140
Biotech Leadership Transformations: Week of May 28th

2018-06-04 biospace
There have been a number of leadership changes in the life sciences industries over the past week. BioSpace compiled a roundup of the changing landscape of the c-suite and boards of directors across the industry.
LPTX DCPH XLRN ARCT ALXN ADHD ICPT ELN KITE ACHN CMTA

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to ALXN / Alexion Pharmaceuticals, Inc. on message board site Silicon Investor.

Alexion Pharmaceuticals, Inc. (ALXN)
CUSIP: 015351109